Refine
Year of publication
- 2018 (1035) (remove)
Document Type
- Journal article (510)
- Doctoral Thesis (415)
- Complete part of issue (51)
- Preprint (22)
- Book article / Book chapter (6)
- Book (5)
- Jahresbericht (4)
- Conference Proceeding (4)
- Working Paper (4)
- Master Thesis (3)
Language
- English (685)
- German (346)
- Spanish (3)
- Multiple languages (1)
Keywords
- Würzburg (50)
- Wuerzburg (49)
- Wurzburg (49)
- Universität (48)
- University (47)
- Parton Distributions (23)
- Hadron-Hadron scattering (experiments) (18)
- Positronen-Emissions-Tomografie (16)
- Extension (14)
- PET (14)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (112)
- Physikalisches Institut (110)
- Graduate School of Life Sciences (82)
- Universität - Fakultätsübergreifend (47)
- Medizinische Klinik und Poliklinik II (41)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (38)
- Klinik und Poliklinik für Nuklearmedizin (36)
- Institut für Anorganische Chemie (33)
- Medizinische Klinik und Poliklinik I (33)
- Institut für Psychologie (27)
Schriftenreihe
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (15)
- Johns Hopkins University School of Medicine (5)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- International Max Planck Research School Molecular Biology, University of Göttingen, Germany (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Universitätsklinikum Würzburg (2)
- ACC GmbH Analytical Clinical Concepts (1)
- Abteilung für Molekulare Onkoimmunologie (1)
ResearcherID
- J-8841-2015 (1)
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra of the human brain, leading to depletion of dopamine production. Dopamine replacement therapy remains the mainstay for attenuation of PD symptoms. Nonetheless, the potential benefit of current pharmacotherapies is mostly limited by adverse side effects, such as drug-induced dyskinesia, motor fluctuations and psychosis. Non-dopaminergic receptors, such as human A2A adenosine receptors, have emerged as important therapeutic targets in potentiating therapeutic effects and reducing the unwanted side effects. In this study, new chemical entities targeting both human A2A adenosine receptor and dopamine D2 receptor were designed and evaluated. Two computational methods, namely support vector machine (SVM) models and Tanimoto similarity-based clustering analysis, were integrated for the identification of compounds containing indole-piperazine-pyrimidine (IPP) scaffold. Subsequent synthesis and testing resulted in compounds 5 and 6, which acted as human A2A adenosine receptor binders in the radioligand competition assay (Ki = 8.7–11.2 μM) as well as human dopamine D2 receptor binders in the artificial cell membrane assay (EC50 = 22.5–40.2 μM). Moreover, compound 5 showed improvement in movement and mitigation of the loss of dopaminergic neurons in Drosophila models of PD. Furthermore, in vitro toxicity studies on compounds 5 and 6 did not reveal any mutagenicity (up to 100 μM), hepatotoxicity (up to 30 μM) or cardiotoxicity (up to 30 μM).